Angeles Therapeutics

Executive Summary

Angeles Therapeutics is a private, next-generation cell therapy company headquartered in Los Angeles, California. Founded in 2020, the company is developing proprietary chimeric antigen receptor (CAR) platforms for both T cells (CAR-T) and natural killer cells (CAR-NK). It claims one of the world's largest portfolios of CAR-based assets, positioning itself for broad oncology targeting. Despite its ambitious portfolio, the company remains in early stages with no disclosed funding, pipeline details, or clinical trial data. The cell therapy landscape is highly competitive, with approved products and many advanced candidates, but Angeles Therapeutics differentiates through its dual CAR-T/CAR-NK focus and potential for off-the-shelf therapies. Execution risk is elevated due to the lack of public development milestones and capital requirements for advancing multiple programs. Conviction score is moderate, reflecting the company's promising platform but early and opaque status.

Upcoming Catalysts (preview)

• Q2 2027Lead IND Filing for First CAR-T Program40% success
• Q1 2027Series A Financing Announcement60% success
• Q4 2026Partnership or Licensing Deal for CAR-NK Platform50% success